National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedGoodwin JS, Zhou J, Kuo YF
Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer.
The researchers compared the risk of jaw osteonecrosis after intravenous (IV) bisphosphonate administered to patients with cancer vs patients without cancer. During follow-up, 40 (0.42 percent) out of 9,482 patients with cancer developed probable jaw osteonecrosis compared with 8 (0.05 percent) out of 16,046 patients without cancer.
AHRQ-funded; HS022134.
Citation: Goodwin JS, Zhou J, Kuo YF .
Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer.
Mayo Clin Proc 2017 Jan;92(1):106-13. doi: 10.1016/j.mayocp.2016.09.015.
.
.
Keywords: Cancer, Osteoporosis, Risk, Medication, Patient-Centered Outcomes Research
Cram P, Wolinsky FD, Lou Y
Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial.
In a clinical trial of 7749 patients, the researchers tested whether usual care augmented by a tailored patient-activation DXA result letter accompanied by an educational brochure would improve guideline-concordant pharmacological treatment compared to usual care only. They found that treatment rates did not improve.
AHRQ-funded; HS023009.
Citation: Cram P, Wolinsky FD, Lou Y .
Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial.
Osteoporos Int 2016 Dec;27(12):3513-24. doi: 10.1007/s00198-016-3681-9.
.
.
Keywords: Education: Patient and Caregiver, Guidelines, Medication, Osteoporosis, Patient and Family Engagement
Fenton JJ, Robbins JA, Amarnath AL
Osteoporosis overtreatment in a regional health care system.
The researchers estimated the frequency of osteoporosis overtreatment in a regional health care system where DXA reports routinely include T scores for anatomic sites (e.g., lateral lumbar spine) that the International Society for Clinical Densitometry does not recommend for osteoporosis diagnosis. They found that two-thirds of new osteoporosis drug prescriptions were potentially inappropriate.
AHRQ-funded; HS022236.
Citation: Fenton JJ, Robbins JA, Amarnath AL .
Osteoporosis overtreatment in a regional health care system.
JAMA Intern Med 2016 Mar;176(3):391-3. doi: 10.1001/jamainternmed.2015.6020.
.
.
Keywords: Shared Decision Making, Diagnostic Safety and Quality, Medication, Osteoporosis